| Dr Trever J Martin, DPM | |
|
1024 E Locust St, Emmett, ID 83617 | |
| (208) 365-2338 | |
| (208) 365-0677 |
| Full Name | Dr Trever J Martin |
|---|---|
| Gender | Male |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 1024 E Locust St, Emmett, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316236797 | NPI | - | NPPES |
| 20005139 | Other | ID | MEDICARE PTAN |
| 820382500 | Other | ID | TAX ID |
| 1316236797 | Other | ID | NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | P-227 (Idaho) | Primary |
| Provider Name | Walter Knox Memorial Hospital |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1063419018 PECOS PAC ID: 7012907785 Enrollment ID: O20040514000512 |
News Archive
Today Biogen Idec announced the company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B.
Frigid weather may seem like a good excuse to avoid workouts, stay inside and overindulge in comfort foods. However, health experts from the University of Missouri have found that these tendencies leave most people feeling less content during the winter months. MU researchers say people should establish new traditions to increase happiness and avoid wintertime woes.
NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.
Merck & Co have finally won the Food and Drugs Administration – FDA'S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Trever J Martin, DPM 1202 E Locust St, Emmett, ID 83617-2715 Ph: (208) 365-2338 | Dr Trever J Martin, DPM 1024 E Locust St, Emmett, ID 83617 Ph: (208) 365-2338 |
News Archive
Today Biogen Idec announced the company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B.
Frigid weather may seem like a good excuse to avoid workouts, stay inside and overindulge in comfort foods. However, health experts from the University of Missouri have found that these tendencies leave most people feeling less content during the winter months. MU researchers say people should establish new traditions to increase happiness and avoid wintertime woes.
NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.
Merck & Co have finally won the Food and Drugs Administration – FDA'S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.
› Verified 8 days ago